BERLIN–(BUSINESS WIRE)–Regulatory News:
NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today the results of its 2021 annual general meeting of shareholders (AGM), which took place on June 24, 2021 at 02.00 p.m. CEST. Shareholders representing a total of 8.83% of the total issued and outstanding share capital on May 27, 2021 were represented by proxy.
All proposed resolutions submitted to the AGM were approved, including the nomination to the Supervisory Board of Susan Coles, Dr. Martine van Vugt and Gregory Weaver and the adoption of the financial results for the fiscal year 2020. The full list of resolutions can be found below. The details of NOXXON’s Supervisory Board including members’ bios are available on the company’s website.
“I am delighted to welcome Susan, Martine and Greg to the NOXXON Supervisory Board. All three of our new colleagues bring in valuable experience and insight, covering medical expertise, clinical development, financing and business development. Their expertise will add to the strength of the NOXXON team, and we look forward to working closely with our CEO Aram to deliver on our ambitious strategy, with data from the Phase 1/2 study of NOX-A12 in brain cancer due in Q4 2021,” said Dr. Maurizio PetitBon, Chairman of the Supervisory Board of NOXXON.
|
Item |
Resolution |
|
|
2.d: Adoption of the annual accounts 2020 |
Accepted |
|
|
2.e: Release from liability of the sole member of the board of directors |
Accepted |
|
|
2.f: Release from liability of the members of the supervisory board |
Accepted |
|
|
3: Re-appointment of Dr. A. Mangasarian as member of the board of directors |
Accepted |
|
|
4.a: Appointment of Susan Coles as member of the supervisory board |
Accepted |
|
|
4.b: Appointment of Dr. Martine van Vugt as member of the supervisory board |
Accepted |
|
|
4.c: Appointment of Gregory Weaver as member of the supervisory board |
Accepted |
|
|
5: Appointment of Baker Tilly (Netherlands) N.V. as statutory auditor for the financial year 2021 |
Accepted |
|
|
6: Partial amendment of the articles of association in relation to the increase of authorised share capital |
Accepted |
|
|
7: Partial amendment of the articles of association in relation to introducing a transitional provision to increase the authorised share capital |
Accepted |
|
|
8: Delegation to the board of directors to issue ordinary shares and to limit or exclude any pre-emptive rights in connection therewith |
Accepted |
|
|
9: Renewal delegation to the board of directors to acquire shares |
Accepted |
|
|
10: Change of the remuneration in the form of shares and rights to subscribe for shares for the members of the board of directors and the supervisory board |
Accepted |
|
|
11: Amendment of Sec. 3.4 of the Remuneration Policy regarding the compensation structure of nonexecutive directors in relation to grant of options |
Accepted |
|
|
12: Amendment of Sec. 3.6 of the Remuneration Policy regarding the compensation for membership of a committee |
Accepted |
The presentation outlining the agenda items and voting results of the AGM is available online. The minutes of the AGM will soon be made available on the NOXXON website (www.noxxon.com).
About NOXXON
NOXXON’s oncology-focused pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking the tumor protection barrier and blocking tumor repair. By neutralizing chemokines in the TME, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. NOXXON’s lead program NOX-A12 has delivered final top-line data from a Keytruda® combination trial in metastatic colorectal and pancreatic cancer patients published at the ESMO conference in September 2020 and based on the trial results, including overall survival and safety profile, further studies are being planned in pancreatic cancer. NOXXON is also studying NOX-A12 in brain cancer in combination with radiotherapy which has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. A trial of NOX-A12 in combination with radiotherapy in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy has delivered interim data from the first two cohorts showing consistent tumor reductions and objective tumor responses. The company’s second clinical-stage asset NOX-E36 is a Phase 2 TME asset targeting the innate immune system. NOXXON plans to test NOX‑E36 in patients with solid tumors. Further information can be found at: www.noxxon.com
Keytruda® is a registered trademark of Merck Sharp & Dohme Corp
https://www.linkedin.com/company/noxxon-pharma-ag
https://twitter.com/noxxon_pharma
Disclaimer
Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.
Contacts
NOXXON Pharma N.V.
Aram Mangasarian, Ph.D.
Chief Executive Officer
Tel. +49 (0) 30 726247 0
amangasarian@noxxon.com
Investor and Media Relations:
LifeSci Advisors
Guillaume van Renterghem
Tel. +41 (0) 76 735 01 31
gvanrenterghem@lifesciadvisors.com
NewCap
Arthur Rouillé
Tel. +33 (0) 1 44 71 00 15
arouille@newcap.fr